Lu Jinmeng, Zhang Chengyu, Yin Mengshuang, You Huili, Xiong Chao, Wu Jing, Gong Ying, Xiao Zhangang, Shen Jing
Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou 646000, China.
Biomolecules. 2025 Jun 22;15(7):912. doi: 10.3390/biom15070912.
VIRMA (also known as KIAA1429), as a core regulatory subunit of the m6A methyltransferase complex, plays a key role in tumorigenesis and progression by dynamically regulating RNA methylation modifications. Studies have shown that VIRMA is aberrantly overexpressed in more than 20 types of malignant tumors, including liver cancer, breast cancer, and lung cancer, and is significantly associated with chromosome 8q amplification and poor prognosis. Its mechanism of action involves regulating the expression of tumor-associated genes through both m6A-dependent and m6A-independent pathways, thereby promoting tumor proliferation, metastasis, and drug resistance. These findings suggest that VIRMA has the potential to serve as a pan-cancer diagnostic and prognostic biomarker. This review summarizes the role of VIRMA in malignant tumors from multiple perspectives and explores its potential applications in clinical diagnosis and treatment.
VIRMA（也称为KIAA1429）作为m6A甲基转移酶复合体的核心调节亚基，通过动态调节RNA甲基化修饰在肿瘤发生和进展中起关键作用。研究表明，VIRMA在包括肝癌、乳腺癌和肺癌在内的20多种恶性肿瘤中异常高表达，且与8号染色体q臂扩增及不良预后显著相关。其作用机制涉及通过m6A依赖和m6A非依赖途径调节肿瘤相关基因的表达，从而促进肿瘤增殖、转移和耐药。这些发现表明，VIRMA有潜力作为一种泛癌诊断和预后生物标志物。本综述从多个角度总结了VIRMA在恶性肿瘤中的作用，并探讨了其在临床诊断和治疗中的潜在应用。
